← Back to Hoxie & Associates LLC
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19539095 | PHARMACEUTICAL COMPOSITION COMPRISING A PRMT5 INHIBITOR AND AN EGFR INHIBITOR | Apeiron Therapeutics (Hong Kong) Ltd. | MOSELEY II, NELSON B | 1642 | §103DP | Non-Final OA | — | Pending | Feb 13, 2026 |
| 19539109 | PHARMACEUTICAL COMPOSITION COMPRISING PRMT5 INHIBITOR AND PD-1/PD-L1 INHIBITOR | Apeiron Therapeutics (Hong Kong) Ltd. | HAVLIN, ROBERT H | 1626 | §103DP | Final Rejection | — | Pending | Feb 13, 2026 |
| 19540268 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | Novaliq GmbH | PALENIK, JEFFREY T | 1615 | §102Other | Final Rejection | — | Pending | Feb 13, 2026 |
| 19374186 | NOVEL PI3K AND/OR PIKK INHIBITORS, ANTIBODY-DRUG CONJUGATES COMPRISING THE SAME AND USES THEREOF | Hutchmed Limited | HUYNH, PHUONG N | 1641 | §112 | Non-Final OA | — | Pending | Oct 30, 2025 |
| 19274087 | O/W-EMULSIONS COMPRISING SEMIFLUORINATED ALKANES | Novaliq GmbH | YU, HONG | 1614 | §103§112DP | Non-Final OA | — | Pending | Jul 18, 2025 |
| 19203107 | PARTICLE SEPARATOR SYSTEM, MATERIALS, AND METHODS OF USE | Levitasbio, Inc. | MARTIN, PAUL C | 1653 | §103§112DP | Non-Final OA | — | Pending | May 08, 2025 |
| 19194059 | ORAL POLYPEPTIDE COMPOSITION | Shenzhen Oralead Pharma Co., Ltd. | YOUNG, MICAH PAUL | 1618 | §103 | Non-Final OA | — | Pending | Apr 30, 2025 |
| 18873307 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. | TRUONG, QUANGLONG N | 1615 | §103§112 | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18869588 | TREATMENT OF CANCER WITH S1P RECEPTOR AGONISTS | Priothera Limited | COLEMAN, BRENDA LIBBY | 1624 | §112 | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18868772 | CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE | Idorsia Pharmaceuticals Ltd. | KOSACK, JOSEPH R | 3991 | §112 | Non-Final OA | — | Pending | Nov 24, 2024 |
| 18868080 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | Idorsia Pharmaceuticals Ltd. | SEUDIEU SEUDIEU, CARINE PATRICIA | 1626 | §103§112Other | Non-Final OA | — | Pending | Nov 21, 2024 |
| 18867252 | IMPROVED SYNTHETIC METHODS FOR MAKING LACTONES | P2 Science, Inc. | CHANDRAKUMAR, NIZAL S | 1625 | §112Other | Non-Final OA | 18d overdue | Pending | Nov 19, 2024 |
| 18952990 | COMPOSITIONS AND METHODS FOR MINIMIZING EFFECTS OF ALCOHOL INTOXICATION | Safety Shot, Inc. | MERCIER, MELISSA S | 1615 | §112DP | Non-Final OA | — | Pending | Nov 19, 2024 |
| 18866978 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | KIFLE, BRUCK | 1624 | §103§112 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18851893 | A FREEZE-DRYING PROCESS FOR AN ADC | Genequantum Healthcare (Suzhou) Co., Ltd. | EVANS, JASMINE AFIYA | 1616 | §103§112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18897877 | SEMIFLUORINATED COMPOUNDS AND THEIR COMPOSITIONS | Novaliq GmbH | PECKHAM, RICHARD GRANT | 1627 | §112DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18847126 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. | SCHMITT, MICHAEL J | 1629 | §112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18847121 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103§112DP | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18843308 | MODULATORS OF ACKR3 AND USES THEREOF | Stichting VU | SEAMAN, D MARGARET M | 1625 | §112 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18820161 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | Osmo Labs, Pbc | AHVAZI, BIJAN | 1763 | §102§112 | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18819236 | CRYSTALS | Aeromics, Inc. | COUGHLIN, MATTHEW P | 1626 | §103§112DP | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18838517 | PROCESS FOR RECOVERING AND PURIFYING VANILLIN | International Flavors & Fragrances, Inc. | ARIANI, KADE | 1651 | §103§112 | Non-Final OA | — | Pending | Aug 14, 2024 |
| 18800808 | FARNESOID X RECEPTOR MODULATORS | Alfasigma S.p.A. | KUCKLA, ANNA GRACE | 1626 | §112DP | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18833346 | NOVEL COMPOSITIONS | Tulex Pharmaceuticals, Inc. | HOLLOMAN, NANNETTE | 1612 | §103§112DP | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18784569 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | Novaliq GmbH | PALENIK, JEFFREY T | 1615 | §103§112Other | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18777765 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | SHIAO, REI TSANG | 1691 | DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18729674 | PROMOTER FOR THE EXPRESSION OF GENES IN PARTICULAR EGR2-POSITIVE CELLS IN LAYER 2/3 OF MOUSE CORTEX | Friedrich Miescher Institute For Biomedical Research | DHAR, MATASHA | 1632 | §112 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18755795 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited | WILLIS, DOUGLAS M | 1624 | DPOther | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18714302 | Rapid T-Cell Manufacturing | Kure Cells, Inc. | EBBINGHAUS, BRIANA NOEL | 1632 | §102§103§112 | Non-Final OA | — | Pending | May 29, 2024 |
| 18670391 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | JAVANMARD, SAHAR | 1622 | §112Other | Non-Final OA | — | Pending | May 21, 2024 |
| 18709201 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. | BERRY, LAYLA D | 1693 | §102§103§112 | Non-Final OA | — | Pending | May 10, 2024 |
| 18705346 | CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd. | BAUER, BRIANNA LEE | 1623 | §112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18703113 | SILYL ETHER DERIVATIVES OF POLYETHER POLYMERS | P2 Science, Inc. | BAHTA, MEDHANIT W | 1692 | §112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18693766 | FORMULATIONS AND USES OF RESVERATROL | Danstar Ferment AG | HEASLEY, MEGHAN CHRISTINE | 1626 | §103§112 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18690068 | GENE THERAPY CONSTRUCT FOR TREATING POMPE DISEASE, PHARMACEUTICAL COMPOSITION, AND METHOD | Beijing Genecradle Pharmaceutical Co., Ltd. | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18686381 | IMMUNOGENIC COMPOSITIONS AND THEIR USE | Osivax Belgique | KINSEY WHITE, NICOLE ERIN | 1672 | §103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18290928 | THERAPEUTIC MUTEINS | Institut National De La Santé Et De Al Recherche Médicale (Inserm) | MIDDLETON, DANAYA L | 1674 | §112 | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18410200 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. | PUTTLITZ, KARL J | 1646 | §102§103§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18408826 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. | PUTTLITZ, KARL J | 1646 | §103§112DP | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18564510 | ANTIBODY SPECIFICALLY BINDING TO ASM PROTEIN | Isu Abxis Co., Ltd. | PRIEST, JESSICA MARIE | 1642 | §101§102§103§112Other | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18504472 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | Montelino Therapeutics, Inc. | COLEMAN, BRENDA LIBBY | 1624 | §112 | Non-Final OA | 27d | Pending | Nov 08, 2023 |
| 18022051 | BACTERIAL TARGETING VECTOR CARRYING CYTOKINE OR POLYNUCLEOTIDE THEREOF AND USE THEREOF IN TUMOR TREATMENT | Shenzhen Synthetica Pioneering Co., Ltd. | XU, QING | 1656 | §102§103§112Other | Final Rejection | — | Pending | Oct 12, 2023 |
| 18481168 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | RODRIGUEZ-GARCIA, VALERIE | 1600 | §103DP | Final Rejection | — | Pending | Oct 04, 2023 |
| 18551396 | METHOD FOR DIAGNOSING DRY MOUTH USING BIOMARKERS | The Regents of the University of California | SITTON, JEHANNE SOUAYA | 1699 | §101§103§112 | Non-Final OA | — | Pending | Sep 19, 2023 |
| 18550088 | THE OXIDATION OF CARBON-HYDROGEN BONDS USING OZONE | P2 Science, Inc. | CUTLIFF, YATE KAI RENE | 1692 | §103§112 | Non-Final OA | — | Pending | Sep 11, 2023 |
| 18464129 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | Team Medical, LLC | SHIN, DANA H | 1635 | §102§103§112DP | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18549446 | Anti-HER2 Antibody-Immune Agonist Conjugate and Applications Thereof | Brightgene Bio-Medical Technology Co., Ltd. | STONEBRAKER, ALYSSA RAE | 1642 | Other | Final Rejection | 14d | Pending | Sep 07, 2023 |
| 18548719 | Method of Evaluating the Biofilm Detachment Efficacy of Compositions | The Ohio State University | SWIFT, CANDICE LEE | 1657 | §101§103§112DP | Final Rejection | 2d overdue | Pending | Sep 01, 2023 |
| 18548833 | TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | Idorsia Pharmaceuticals Ltd. | CHO, DAVID H | 1693 | DP | Final Rejection | 9d | Pending | Sep 01, 2023 |
| 18353653 | VISUAL CONTINUOUS SPATIAL DIRECTED EVOLUTION METHOD | Shenzhen Institutes Of Advanced Technology | BOESEN, CHRISTIAN C | §101§103Other | Non-Final OA | — | Pending | Jul 17, 2023 | |
| 18261446 | CHOCOLATE COMPOSITION AND METHOD FOR OBTAINING THE SAME | Barry Callebaut AG | MERRIAM, ANDREW E | 1791 | §103§112 | Non-Final OA | — | Pending | Jul 13, 2023 |
| 18256817 | HDAC6 BINDING PROTEINS AND THEIR ANTI-VIRAL USE | UNIVERSITY OF ZURICH | TAYLOR, LIA ELAN | 1641 | §112 | Final Rejection | 55d | Pending | Jun 09, 2023 |
| 18320173 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | CHONG, YONG SOO | 1623 | DP | Final Rejection | — | Pending | May 18, 2023 |
| 18298059 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | Petragen, Inc. | SZNAIDMAN, MARCOS L | 1628 | §112 | Final Rejection | 34d | Pending | Apr 10, 2023 |
| 18029518 | Prebiotic Oral Care Compositions and Methods | UNIVERSITEIT GENT | LIU, TRACY | 1614 | §103 | Non-Final OA | 15d | Pending | Mar 30, 2023 |
| 18042103 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. | FETTEROLF, BRANDON J | 1626 | §103 | Non-Final OA | 3d overdue | Pending | Feb 17, 2023 |
| 18040618 | PHARMACEUTICAL COMPOSITION OF AQUAPORIN INHIBITOR AND PREPARATION METHOD THEREOF | Aeromics, Inc. | ARNOLD, ERNST V | 1613 | §103§112DP | Non-Final OA | — | Pending | Feb 03, 2023 |
| 18007018 | NOVEL USES | Intra-Cellular Therapies, Inc. | SHOWALTER, ALEXANDER KEITH | 1629 | §103 | Non-Final OA | 60d overdue | Pending | Jan 26, 2023 |
| 18066883 | METHODS OF TREATMENT WITH S1P RECEPTOR MODULATORS | Priothera Limited | SHOWALTER, ALEXANDER KEITH | 1629 | §103 | Final Rejection | 60d overdue | Pending | Dec 15, 2022 |
| 18001764 | NOVEL ISOMERIC COMPOUNDS COMPRISING A RING-OPENED THIOSUCCINIMIDE GROUP, AN OLIGOPEPTIDE FRAGMENT AND A CHIRAL MOIETY | Genequantum Healthcare (Suzhou) Co., Ltd. | NGUYEN, TAM M | 1771 | §103 | Final Rejection | 25d overdue | Pending | Dec 14, 2022 |
| 17996276 | USE OF AN ORPHAN MOTIF TO INCREASE EXPRESSION OF A HETEROLOGOUS TRANSGENE | Friedrich Miescher Institute For Biomedical Research | HAMMELL, NEIL P | 1681 | §102DP | Non-Final OA | — | Pending | Oct 14, 2022 |
| 17917337 | USE OF BROMODOMAIN INHIBITORS FOR TREATMENT OF HUNTINGTON'S DISEASE | Rumi Scientific Holdings, Inc. | SIMMONS, CHRIS E | 1622 | §103§112 | Non-Final OA | 15d | Pending | Oct 06, 2022 |
| 17758352 | COMPOSITIONS HAVING THIOREDOXIN ACTIVITY AND RELATED METHODS | Orpro Therapeutics, Inc. | KOMATSU, LI N | 1658 | DP | Final Rejection | — | Pending | Jul 01, 2022 |
| 17751512 | SUSPENSION COMPRISING A PROTEIN PARTICLE SUSPENDED IN A NON-AQUEOUS VEHICLE | Novaliq GmbH | HOERNER, PAUL ELLSWORTH | 1611 | §103§112 | Non-Final OA | — | Pending | May 23, 2022 |
| 17597903 | METHODS FOR TREATING TUMORS | Nh Theraguix | PERREIRA, MELISSA JEAN | 1618 | §103Other | Non-Final OA | — | Pending | Jan 28, 2022 |
| 17350427 | SEMIFLUORINATED COMPOUNDS | Novaliq GmbH | MOU, LIYUAN | 1628 | §103DP | Final Rejection | 25d overdue | Pending | Jun 17, 2021 |
| 17342057 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF BILE ACID DERIVATIVES | Alfasigma S.p.A. | PECKHAM, RICHARD GRANT | 1627 | §103DP | Final Rejection | 26d | Pending | Jun 08, 2021 |
| 17127867 | METHODS OF SCHIZOPHRENIA TREATMENT | Intra-Cellular Therapies, Inc. | LEE, ANDREW P | 1691 | §103 | Final Rejection | — | Pending | Dec 18, 2020 |
